ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Open access · bronzeAbstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- Reply to S. Rossi et al and P. Palassin et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
8 authors at 1 institution in 1 country.
Simone RossiSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.ORCID 0000-0001-7044-983X
Ilaria CaniSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Emanuel RaschiSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.ORCID 0000-0003-0487-7996
Francesca ComitoSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.ORCID 0000-0002-8591-0788
Rita RinaldiSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Andrea ArdizzoniSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Maria GuarinoSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.ORCID 0000-0002-8894-2187
Francesco GelsominoSimone Rossi, MD, and Ilaria Cani, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Emanuel Raschi, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy; Francesca Comito, MD, PhD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Rita Rinaldi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Andrea Ardizzoni, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; Maria Guarino, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; and Francesco Gelsomino, MD, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy.ORCID 0000-0002-9204-1728
Istituto delle Scienze Neurologiche di Bologna · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
MyocarditisHumansImmune Checkpoint InhibitorsImmunotherapyPatientsImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.